



COVID-19 Reimbursable Laboratory Codes Fee Schedule

The Centers for Medicare and Medicaid Services (CMS) have announced new Healthcare Common Procedure Coding System (HCPCS) codes for healthcare providers and laboratories to use when testing patients for the novel coronavirus (COVID-19). Additionally, the American Medical Association (AMA) Current Procedural Terminology (CPT) Editorial Panel has also created codes for COVID-19 laboratory tests. In response, the Medicaid fee-for-service (FFS) program is reimbursing for these codes at 100% of the Medicare rate. The following fee schedule is a summary of the codes, their descriptions, their effective dates, and the FFS reimbursement rate.

If you have any questions about the contents of this fee schedule for laboratories, please contact Tenesha Lynch, Medical Care Program Specialist II, at tenesha.lynch@maryland.gov.

For questions related to MCOs and Self-Referred Services, please contact Pam Williams, HealthChoice Administrator, at pam.williams@maryland.gov.

COVID-19 Reimbursable Laboratory Codes Fee Schedule

Code	Effective Date	CPT or HCPCS	Description	FFS Rate
U0001	2/4/20	HCPCS	CDC 2019 Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel	\$35.92
U0002	2/4/20	HCPCS	2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC	\$51.33
87635	3/16/20	CPT	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique	\$51.33
86328	4/10/20	CPT	Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (e.g., reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	\$45.23
86769	4/10/20	CPT	Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	\$42.13
U0003 End date 5/11/23	4/14/20	HCPCS	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R	\$100.00
U0004 End date 5/11/23	4/14/20	HCPCS	2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R	\$100.00
0202U	5/20/20	HCPCS	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	\$416.78
87426	6/25/20	CPT	Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA],	\$45.23

			immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (e.g, SARS-CoV, SARSCoV-2 [COVID-19])	
0223U	6/25/20	HCPCS	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	\$416.78
0224U	6/25/20	HCPCS	Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), includes titer(s), when performed (Do not report 0224U in conjunction with 86769)	\$42.13
0225U	8/10/20	HCPCS	Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected	\$416.78
0226U	8/10/20	HCPCS	Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), ELISA, plasma, serum	\$42.28
86408	8/10/20	CPT	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); screen	\$42.13
86409	8/10/20	CPT	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); titer	\$105.33
86413	9/8/20	CPT	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) antibody, quantitative.	\$42.13
87636	10/6/20	CPT	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) antibody, quantitative.	\$142.63
87637	10/6/20	CPT	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus	\$142.63

			disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique	
87811	10/6/20	CPT	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	\$41.38
0240U	10/6/20	HCPCS	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected	\$142.63
0241U	10/6/20	HCPCS	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus [RSV]), upper respiratory specimen, each pathogen reported as detected or not detected	\$142.63
87428	11/10/20	CPT	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B SD: SARSCOV & INF VIR A&B AG IA	\$73.49
	05/01/22			\$30.94

When billing for HCPCS codes U0003 and U0004, please note the following:

- 1) U0003 should identify tests performed with high throughput technologies that would otherwise be billed using CPT code 87635.
- 2) U0004 should identify tests performed with high throughput technologies that would otherwise be billed using U0002.
- 3) Neither U0003 nor U0004 should be billed for tests that detect COVID-19 antibodies.

Specimen Collection for Purposes of COVID-19 Testing

Effective Date	HCPCS Code	Description	FFS Rate
3/1/20 End date 5/11/23	G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), any specimen source	\$23.46
3/1/20 End date 5/11/23	G2024	Specimen collection for severe acute respiratory syndrome coronavirus2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), from an individual in a SNF or by a laboratory on behalf of a HHA, any specimen source	\$25.46

Independent laboratories can bill FFS for the specimen collection fee. The specimen collection fee applies if the specimen is collected by trained laboratory personnel from a homebound individual or non-hospital inpatient. Excluded are specimens that only require the services of a messenger to pick up the specimen or when a patient collects his or her own specimen.